Last Updated on September 7, 2024 by The Health Master
Delhi High Court
In a significant development for the Indian pharmaceutical industry, the Delhi High Court has provided interim relief to several companies affected by the recent ban on 156 fixed dose combinations (FDCs) imposed by the Central government.
The ban, which came into effect on August 2, 2024, has raised concerns about the availability of essential medicines and the potential impact on public health.
The FDC Ban and Legal Challenges
The Central government’s decision to ban 156 FDCs was based on the recommendations of an expert committee, which deemed these combinations as irrational and potentially harmful.
The banned FDCs included common cold, fever, antibacterial, and antifungal drugs.
Several pharmaceutical companies challenged the ban in the Delhi High Court, including:
- Cipla,
- Zydus Healthcare, and
- Mankind Pharma.
They argued that the government’s decision was arbitrary and lacked proper justification.
The companies also expressed concerns about the potential impact of the ban on patients who rely on these FDCs.
Relevant article: 156 Drugs banned in India: Download list
Court’s Interim Order
In response to the petitions filed by the pharmaceutical companies, the Delhi High Court issued an interim order on September 2, 2024.
The court granted interim protection to the companies, allowing them to continue distributing the remaining stock of these banned FDCs until further notice.
The court also directed the companies to submit details of their stock of the banned drugs within three days.
The Union of India was given four weeks to file a counter affidavit.
Previous Court Rulings and Government Actions
This is not the first time that the Delhi High Court has intervened in matters related to FDC bans.
In June 2023, the court granted interim relief to companies affected by an earlier ban on 14 FDCs.
The government’s decision to ban FDCs is based on its assessment of the potential risks associated with these combinations.
The Drugs Technical Advisory Board (DTAB) has also recommended the ban, citing the lack of therapeutic justification for the ingredients contained in these FDCs.
Impact on Public Health and Industry
The ban on FDCs has raised concerns about the availability of essential medicines and the potential impact on public health.
Many patients rely on these FDCs for their healthcare needs.
The ban has also had a significant impact on the pharmaceutical industry.
Several companies have been affected by the ban, and there are concerns about job losses and economic consequences.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
156 Drugs banned in India: Download list
Govt ban on Pain relief combination S(+)Etodolac & Paracetamol
OTC sale of MTP Kits banned: Karnataka
DCC Approves Ban on Harmful Antibiotics in Food Products
DTAB: Pain Relief Combo Faces New Ban Recommendation
Impact of Ban on Manufacturing of Food in Pharma Units: A Plea from SPIC
Govt to frame Disposal Policy for Expired Drugs
FDA Maharashtra cracks down on illegal sale of drugs
Pharma Industry seeks amendments to DPCO 2013
Telangana DCA Busts Illegal Drug Trade in Hyderabad
Drug recall: Dr Reddy’s, Lupin recall drugs over quality issue
Pharma Companies Under Scrutiny: New Rules for Marketing Practices
DCGI granted approval for Eye Drops to treat Presbyopia
Pakistan: Drug Production Quality Under Scrutiny, Concerns Raised in Senate Committee
NDPS: Illegal Drug Manufacturing Unit busted in East Godavari
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
